Felix Funk

ORCID: 0000-0003-0794-1105
Publications
Citations
Views
---
Saved
---
About
Contact & Profiles
Research Areas
  • Iron Metabolism and Disorders
  • Hemoglobinopathies and Related Disorders
  • Parathyroid Disorders and Treatments
  • Erythropoietin and Anemia Treatment
  • Magnesium in Health and Disease
  • Trace Elements in Health
  • Aluminum toxicity and tolerance in plants and animals
  • Plant Micronutrient Interactions and Effects
  • Folate and B Vitamins Research
  • Nanoparticle-Based Drug Delivery
  • Porphyrin Metabolism and Disorders
  • Membrane-based Ion Separation Techniques
  • Cassava research and cyanide
  • Enzyme Catalysis and Immobilization
  • Potassium and Related Disorders
  • Biomedical Research and Pathophysiology
  • RNA regulation and disease
  • Iron oxide chemistry and applications
  • Chromium effects and bioremediation
  • Advanced Drug Delivery Systems
  • Heterotopic Ossification and Related Conditions
  • Diabetes Treatment and Management
  • Plant nutrient uptake and metabolism
  • Genetic Syndromes and Imprinting
  • Enzyme Production and Characterization

Vifor Pharma (Switzerland)
2013-2022

Vifor Pharma (United States)
2011-2015

Hospital Universitari Arnau de Vilanova
2013

Biomedical Research Institute of Lleida
2013

University Hospital of Lausanne
2013

University of Lausanne
2013

University of St. Gallen
2011

École Polytechnique Fédérale de Lausanne
1997-2003

ETH Zurich
1985-1999

Board of the Swiss Federal Institutes of Technology
1985-1986

The reductive mobilisation of iron from ferritin, the principal protein storage, was studied. kinetic characteristics release by dithionite, thioglycollate, and dihydroriboflavin 5′-phosphate (FMNH2) were found to differ widely. dependence on pH is most pronounced for dithionite reduction which proceeds 100 times faster at 4 than 7. experimental data can be consistently explained in terms specific interactions products or educts with interfacial iron(III) hydroxide ferritin core. Surface...

10.1111/j.1432-1033.1985.tb09177.x article EN European Journal of Biochemistry 1985-10-01

Hyperphosphatemia in advanced chronic kidney disease (CKD) necessitates the use of phosphate binders. This vitro study assessed binding and Fe release properties novel iron-based binder PA21.Phosphate adsorption were under conditions simulating administration PA21 on an empty stomach full across a pH range to which would be exposed during passage through gastrointestinal (GI) tract.PA21 showed robust capacity over entire physiologically relevant range. The high at low indicates that could...

10.5414/cn108119 article EN Clinical Nephrology 2014-03-23

Elevated serum phosphorus, calcium, and fibroblast growth factor 23 (FGF23) levels are associated with cardiovascular disease in chronic renal disease. This study evaluated the effects of sucroferric oxyhydroxide (PA21), a new iron-based phosphate binder, versus lanthanum carbonate (La) sevelamer (Se), on FGF23, intact parathyroid hormone (iPTH) concentrations, development vascular calcification adenine-induced failure (CRF) rats. After induction CRF, function was significantly impaired all...

10.1155/2015/515606 article EN cc-by BioMed Research International 2015-01-01

Chronic renal failure (CRF) is associated with the development of secondary hyperparathyroidism and vascular calcifications. We evaluated efficacy PA21, a new iron-based noncalcium phosphate binder, in controlling phosphocalcic disorders preventing calcifications uremic rats. Rats adenine-diet-induced CRF were randomized to receive either PA21 0.5, 1.5, or 5% CaCO<sub>3</sub> 3% diet for 4 weeks, compared nonuremic control groups. After weeks binder treatment, serum calcium, creatinine, body...

10.1124/jpet.113.204792 article EN Journal of Pharmacology and Experimental Therapeutics 2013-05-22

10.1023/a:1015552311359 article EN Hyperfine Interactions 2001-01-01

Intravenous (IV) iron nanoparticle preparations are widely used to treat deficiency. The mechanism of mononuclear phagocyte system-mediated clearance IV nanoparticles is unknown. early uptake and homeostasis after injection ferric carboxymaltose (FCM) in mice was studied. An increase serum observed at 2.5 h followed by a return baseline 24 h. circulating monocytes observed, particularly Ly6Chi Ly6Clow. FCM also associated with time-dependent decrease liver Kupffer cells (KCs) monocytes....

10.3390/ijms23052666 article EN International Journal of Molecular Sciences 2022-02-28

Abstract Aims Iron deficiency is frequently observed in patients with acute coronary syndrome and associates poor prognosis after myocardial infarction (AMI). Anaemia linked to dysregulation of iron metabolism, red blood cell dysfunction, increased reactive oxygen species generation. supplementation chronic heart failure safe improves cardiac exercise capacity. Increases during ischaemia or immediately reperfusion are associated detrimental effects on left ventricular (LV) function. The...

10.1002/ehf2.13639 article EN ESC Heart Failure 2021-10-11

Since anthracycline-induced cardiotoxicity (AIC), a complication of anthracycline-based chemotherapies, is thought to involve iron, concerns exist about using iron for anaemia treatment in anthracycline-receiving cancer patients. This study evaluated how intravenous ferric carboxymaltose (FCM) modulates the influence deficiency (IDA) and doxorubicin (3–5 mg per kg body weight [BW]) on oxidative/nitrosative stress, inflammation, cardiorenal function spontaneously hypertensive stroke-prone...

10.1155/2014/570241 article EN cc-by Chemotherapy Research and Practice 2014-04-30

Abstract Introduction Sucroferric oxyhydroxide (PA21) is an efficacious, well-tolerated iron-based phosphate binder and a promising alternative to existing compounds. We compared the effects of PA21 with those conventional on renal function, mineral homeostasis vascular calcification in chronic kidney disease–mineral bone disorder (CKD-MBD) rat model. Methods To induce stable failure, rats were administered 0.25% adenine diet for 8 weeks. Concomitantly, treated vehicle, 2.5 g/kg/day PA21,...

10.1093/ndt/gfaa080 article EN cc-by-nc Nephrology Dialysis Transplantation 2020-03-25

Inhibition of β-glucosidase activity by Cu(II), Zn(II) and Ni(II) was investigated as a function pH buffer type. Both factors were found to exert strong effect on the enzyme. All three heavy metals inhibited enzyme in acetate buffer. At metal concentrations 0.6 mM, Zn Ni reduced 25-30% under optimal conditions (pH 5-5.2). Under same conditions, Cu showed an even more pronounced inhibitory than Ni. In presence mM Cu, lowered 90% comparison free systems. contrast these results, no inhibition...

10.3109/14756369909030329 article EN Journal of enzyme inhibition 1999-01-01

Summary We investigated the effect of goethite and copper on almond β‐glucosidase activity. The activity was found to be inhibited at dissolved concentrations exceeding 0.2 m . Copper most influential in pH range 5–5.5, which enzyme reduced by 50% or more total compared with copper‐free assays. At 4, presence 15% most. caused a shift optimum towards lower pH. Goethite did not influence significantly, although up 95% adsorbed its surface. adsorption seemed principally non‐electrostatic forces...

10.1046/j.1365-2389.1998.00135.x article EN European Journal of Soil Science 1998-03-01

Cellular iron supply is required for various biochemical processes. Measuring bioavailable in cells aids obtaining a better understanding of its activities but technically challenging. Existing techniques have several constraints that make precise localization difficult, and the lack functional readout makes it unclear whether tested labile available metalloproteins. Here, we use geNOps; ferrous iron-dependent genetically encoded fluorescent nitric oxide (NO) biosensor, to measure cellular...

10.3390/bios12100903 article EN cc-by Biosensors 2022-10-21

Under physiological conditions, ferric ions are essentially insoluble because of the formation polynuclear hydroxo-bridged complexes. Ferrous more soluble but may produce hydroxyl radicals on reaction with hydrogen peroxide. Chelation and ferrous organic ligands prevent these undesirable reactions. Alternatively, iron(III)-hydroxide/oxide can be stabilized solubilized by tight interactions carbohydrates. The data presented in this work show that, its physicochemical properties,...

10.1055/s-0031-1296684 article EN Arzneimittelforschung 2011-12-21

Simple iron salts, such as sulphate, often interact with food and other medications reducing bioavailability toler-ability. Iron(III)-hydroxide polymaltose complex (IPC, Maltofer<sup>©</sup>) provides a soluble form of non-ionic iron, making it an ideal oral supplementation. The physicochemical properties IPC predict low potential for interactions. effects co-administration aluminium hydroxide (CAS 21645-51-2), acetylsalicylic acid 50-78-2), bro-mazepam 1812-30-2), calcium acetate 62-54-4),...

10.1055/s-0031-1296685 article EN Arzneimittelforschung 2011-12-21

The rates of reaction various exogenic iron(III) complexes with deuteroporphyrin IX in isolated mitochondria to form deuterohaem were measured. Ferritin was shown supply iron readily for haem synthesis if the ferritin reductively mobilised by mitochondrial respiratory chain succinate as substrate and FMN mediator. In contrast, polynuclear able without added FMN. Rates formation are about five times higher lowest units than ferritin. Sorbitol, gluconate, bovine serum albumin used scavengers...

10.1111/j.1432-1033.1986.tb09669.x article EN European Journal of Biochemistry 1986-06-01

Objective: Cardiovascular disease is a major cause of mortality in patients with chronic kidney (CKD). Elevated serum phosphate and FGF23 are associated cardiovascular CKD. Current therapy focuses on decreasing phosphorus using binders. PA21 new iron-based binder. Few studies have analysed how to suppress up-regulation To evaluate the effects compared other binders as lanthanum carbonate (La) sevelamer (Se) FGF23, phosphorus, calcium, iPTH concentrations investigate potential effect...

10.1097/01.hjh.0000467394.66592.05 article EN Journal of Hypertension 2015-06-01
Coming Soon ...